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Introduction: Sunitinib was developed as a molecular-targeted drug to treat advanced renal cell carcinoma. It is
not yet known whether liver damage occurs in patients with liver metastases of renal cell carcinoma after sunitinib
administration. Here, we report the case of a patient with an inoperable massive liver metastasis of renal cell
carcinoma for whom sunitinib administration was dramatically effective with no obvious evidence of liver damage.
As a result, the liver metastasis could be resected. We emphasize the dramatic reduction in liver metastasis with
sunitinib treatment, and the histopathological effects of sunitinib on the non-tumorous liver parenchyma.
Case presentation: A 54-year-old Japanese woman was diagnosed with right renal cell carcinoma and underwent
right nephrectomy 12 years earlier. She presented to a local clinic with right abdominal pain. A computed
tomography scan showed a massive liver metastasis occupying her right hepatic lobe, and she was referred to our
hospital for treatment. The diagnosis was not only liver metastasis, but also left renal metastasis. Oral administration
of tyrosine kinase inhibitor sunitinib was started. Adverse events due to sunitinib included liver dysfunction,
thrombocytopenia, and decreased hemoglobin, but she completed eight courses with the help of drug holidays
and dose adjustments. Post-treatment computed tomography showed a dramatic reduction in size of her liver
metastasis, enabling right lobectomy of her liver. Histopathological findings showed no obvious liver damage due
to chemotherapy in non-cancerous parenchymal areas.
Conclusions: With the availability of sunitinib, some patients with potentially unresectable massive liver
metastases of renal cell carcinoma may be able to undergo major hepatectomy curatively and safely with little
histopathological damage to non-tumorous liver parenchyma, thus improving their prognosis.
Keywords: Chemotherapy, Liver damage, Liver metastasectomy, Liver metastasis, Renal cell carcinoma, SunitinibIntroduction
Following the introduction of new anticancer agents in
recent years, multimodal therapy incorporating surgical
resection for metastatic liver cancer has been reported
to be effective [1]. However, some cases in which chemo-
therapy caused liver damage have also been reported.
Oxaliplatin, which is frequently used to treat liver metas-
tases of colon cancer, characteristically causes sinusoidal
dilatation, whereas irinotecan causes nonalcoholic
steatohepatitis (NASH) [2]. Sunitinib and sorafenib, which
were developed as molecular-targeted drugs to treat
advanced renal cell carcinoma, mainly block vascular* Correspondence: takahara@iwate-med.ac.jp
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reproduction in any medium, provided the orendothelial growth factor and platelet-derived growth
factor receptor tyrosine kinases, and thereby inhibit tumor
growth and angiogenesis. Sunitinib was approved by the
United States Food and Drug Administration in 2006
and was launched in Japan in June 2008 as a drug for
the treatment of inoperable or metastatic renal cell
carcinoma and imatinib-resistant gastrointestinal stro-
mal tumor (GIST). A metastasectomy in renal cell
carcinoma after neoadjuvant therapy with sunitinib
[3], and the use of sunitinib for a patient with GIST
in the neoadjuvant setting to achieve complete surgical
resection [4] has been reported. Whether liver damage
occurs in patients with liver metastases of renal cell
carcinoma after sunitinib administration is not yet known.
Here, we report a case in which sunitinib administration
was dramatically effective with no obvious evidence ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metastasis of renal cell carcinoma. Treatment by sunitinib
enabled subsequent hepatectomy to be performed safely.
We emphasize the dramatic reduction in liver metasta-
sis with sunitinib treatment, and the histopathological ef-
fects of sunitinib on the non-tumorous liver parenchyma.
Case presentation
A 54-year-old Japanese woman was diagnosed with right
renal cell carcinoma, and she underwent right nephrec-
tomy in the Department of Urologic Surgery at our
hospital. The size of her tumor was 80mm. A diagnosis
of T2N0M0 Stage II was made based on histopatho-
logical findings. The histological subtype of the renal cell
carcinoma was clear cell. After 12 years she began to feel
right abdominal pain and was examined at a local clinic.
A computed tomography (CT) scan showed a massive
liver metastasis occupying her right hepatic lobe, as
well as a left renal metastasis. She was referred to the
Department of Urologic Surgery at our hospital forFigure 1 Abdominal computed tomography before sunitinib adminis
and there is also a left renal metastasis.treatment, and oral sunitinib was started. A pre-treatment
abdominal CT showed a massive liver metastasis measur-
ing 22cm × 17cm in her right hepatic lobe, and a left
renal metastasis of which the largest diameter was 4cm.
Neither ascites nor lymph node metastases were present
(Figure 1). The tumor markers carcinoembryonic antigen
and carbohydrate antigen 19-9 were both within normal
limits. Sunitinib was administered with the standard
regimen of 50 mg/day for 4 weeks followed by a 2-week
drug holiday. According to the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 4.0, adverse events during oral administration
included grade 3 liver dysfunction, thrombocytopenia, and
decreased hemoglobin during course 1; grade 2 neutro-
penia during course 6; and grade 2 renal dysfunction and
hypothyroidism at the end of course 8. However, with
the introduction of drug holidays, dose adjustments
(37.5mg to 50mg/day, increased or decreased according to
the severity of side effects), and changes in the administra-
tion method (from four doses/two holidays to two doses/tration. A massive liver metastasis is present in the right hepatic lobe,
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courses. A CT scan after the completion of the eight
courses of sunitinib showed that her liver metastasis
had shrunk dramatically to a long diameter of 9cm. Her
left renal metastasis had shrunk to a long diameter of 1cm
(Figure 2). According to the guidelines of the Response
Evaluation Criteria in Solid Tumours [5], a 73% decrease
in the size of a tumor of the liver is defined as partial
remission. The preoperative indocyanine green retention
rate at 15 minutes was 18%. Based on these results, right
lobectomy of her liver was performed to remove the renal
cell carcinoma liver metastasis, which had been dramatic-
ally reduced by sunitinib. During surgery, laparotomy was
performed using a J-shaped incision. Her right hepatic
artery and the right branch of her portal vein were
transected in that order, and hepatic parenchyma resec-
tion was performed using a combination of the liver hang-
ing maneuver and an anterior approach. Next, her right
hepatic duct was transected. Tumor thrombosis was
present in her right hepatic vein, and this was excised as
far as possible. Her liver was normal, showing no visible
effects of chemotherapy. The excised specimen measured
92mm × 78mm. The tumor was covered by a capsule,
and its interior showed widespread brownish color-
ation, indicating necrosis (Figure 3).
Immunohistopathology showed that her tumor was
CD10(+), cytokeratin (CK)7(+), and CK20(−), and a diag-
nosis of renal cell carcinoma liver metastasis was made.Figure 2 Abdominal computed tomography after sunitinib administraHematoxylin and eosin staining of her non-tumorous
liver tissue showed no sinusoidal dilatation, with a
Rubbia-Brandt score of 0, and the nonalcoholic fatty liver
disease (NAFLD) activity score was 1, with no obvious
steatohepatitis (Figure 4).
The patient’s postoperative course was uneventful, and
she was discharged after 13 days. Radiofrequency ablation
was performed on her left renal metastasis at 1 month
after discharge. At the time of writing, 1 year after surgery,
no recurrence has been observed in either her liver or her
left kidney.
Discussion
Multiple liver metastases are frequently seen when renal
cell carcinoma metastasizes to the liver; the frequency of
solitary metastasis is 2% to 4% [6]. For this reason, there
have been few reports of resection of liver metastatic
foci. There is no single consistent view on the surgical
indications for renal cell carcinoma liver metastasis.
Stief et al. [7] performed hepatectomy for 13 patients
with liver metastases, four of whom died from complica-
tions, and they reported that patients should be selected
carefully. Staehler et al. [8] performed a retrospective
comparative analysis of 88 patients with renal cell carcin-
oma liver metastases; liver metastases were resected in 66
and not resected in 20, forming the control group. The
5-year survival was 62.2% in the resection group and
29.3% in the control group. The authors stated that livertion. The liver metastasis has liquefied and shrunk dramatically.
Figure 3 Excised specimen. The tumor is covered in a capsule,
with widespread necrosis inside.
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the treatment of metastatic liver carcinoma, and meta-
static foci should be resected when technically possible.
The frequency of adverse events during sunitinib treat-
ment tends to be higher in Japanese patients than in
Western patients [9], and drug holidays are obligatory in
many cases. Because longer drug holidays are unwel-
come from the viewpoint of limiting disease progression,
it is very important to devise ways of adjusting dosage
and methods of use to ensure that drug holidays do not
exceed the minimum necessary. Reported side effects
include thrombocytopenia, leukopenia, hypothyroidism,
cardiac dysfunction, hand-and-foot syndrome, skin dam-
age, diarrhea, and hypertension. Since side effects
frequently appear early on, careful monitoring is re-
quired. In the present case, grade 3 liver dysfunction,
thrombocytopenia, and decreased hemoglobin wereFigure 4 Histopathological findings of background liver
(hematoxylin and eosin staining ×100). No sinusoidal dilatation
or steatohepatitis is present.present during course 1; grade 2 neutropenia occurred
during course 6; and grade 2 renal dysfunction and
hypothyroidism were seen at the end of course 8. How-
ever, with the inclusion of drug holidays, dose adjust-
ments, and changes in the administration method, the
patient was able to complete eight courses. We consid-
ered the renal toxicity of sunitinib treatment might be
caused by only one kidney. In this case both renal and
liver dysfunctions were transient, and recovered through
the introduction of drug holidays and dose adjustments.
Multimodal therapy incorporating new anticancer
agents for metastatic liver cancer is highly effective for
liver metastases of colon cancer in particular but, at the
same time, the liver damage caused by regimens including
oxaliplatin or irinotecan means that caution is required
during surgical hepatectomy. To investigate whether
liver damage occurred during the use of sunitinib in
the present patient, histopathological evaluation of
sinusoidal dilatation in non-tumorous liver tissue was
carried out by scoring according to the method of
Rubbia-Brandt et al. [10], and the NAFLD activity score
was used to evaluate NASH by the method of Kleiner
et al. [11]. The liver was almost normal, with a sinusoidal
dilatation score of 0 and an NAFLD activity score of 1,
indicating no liver damage due to sunitinib.
There are very few reports of patients with massive
liver metastases in whom liver metastasis resection has
been performed after sunitinib administration. Although
this means that it is still unclear whether sunitinib
causes liver damage, in the present case, sunitinib was
dramatically effective, enabling hepatectomy to be
performed with no complications. Hepatectomy can also
be regarded as a valuable tool from an oncological
standpoint. The present histopathological results for the
effects of sunitinib on the non-tumorous liver tissue
might not be the same in all cases; further investigations
involving a greater number of cases are required.
Conclusions
In conclusion, with the availability of sunitinib, some pa-
tients with potentially unresectable massive liver metas-
tases of renal cell carcinoma may be able to undergo
major hepatectomy curatively and safely with little histo-
pathological damage to non-tumorous liver parenchyma,
thus improving their prognosis.
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